Company Encyclopedia
View More
name
ZHONGSHENGYAOYE
002317.SZ
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive.
3.157 T
002317.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking90/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-4.69%D
    • Profit Margin-8.06%D
    • Gross Margin54.27%B
  • Growth ScoreD
    • Revenue YoY0.04%C
    • Net Profit YoY-248.88%E
    • Total Assets YoY-11.21%E
    • Net Assets YoY-9.19%D
  • Cash ScoreD
    • Cash Flow Margin-1240.31%E
    • OCF YoY0.04%C
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreA
    • Gearing Ratio20.16%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    In half a day, the main funds increased their positions in the pharmaceutical and biotechnology sector while selling off the electronics sector

    In the morning, the main funds had a net inflow into sectors such as pharmaceuticals and biotechnology, banking, and real estate, while there was a net outflow from sectors like electronics, electrical equipment, and basic chemicals. Specifically, in terms of individual stocks, WTECL, ZHONGSHENGYAOYE, and ADDSINO saw net inflows of 1.883 billion yuan, 1.344 billion yuan, and 1.215 billion yuan, respectively. On the outflow side, Zhaoyi Innovation, Beijing Junzheng, and TBEA were sold off with net outflows of 1.314 billion yuan, 908 million yuan, and 895 million yuan. (First Financial)

    36Kr·
    SH
    600157
    +3.11%
    SZ
    000547
    +10.00%
    SZ
    002317
    -2.30%
    36Kr·
    SH
    600157
    +3.11%
    SZ
    000547
    +10.00%
    SZ
    002317
    -2.30%

    ZHONGSHENGYAOYE: Net profit in the third quarter was 62.6822 million yuan, a year-on-year increase of 2.10%

    ZHONGSHENGYAOYE announced that the revenue for the third quarter was 589 million yuan, an increase of 8.35% year-on-year; the net profit was 62.6822 million yuan, an increase of 2.10% year-on-year. The revenue for the first three quarters was 1.889 billion yuan, a decrease of 1.01% year-on-year; the net profit was 251 million yuan, an increase of 68.40% year-on-year

    Zhitong·
    SZ
    002317
    -2.30%
    Zhitong·
    SZ
    002317
    -2.30%

    ZHONGSHENGYAOYE: Subsidiary receives approval notice for the listing application of polyvinyl alcohol chemical raw materials

    ZHONGSHENGYAOYE's wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., recently received the notice of approval for the marketing application of polyvinyl alcohol chemical raw materials from the National Medical Products Administration. Polyvinyl alcohol is a high molecular polymer with hydrophilicity and film-forming properties, which can be used for eye lubrication to prevent and treat symptoms such as dry eyes, foreign body sensation, and eye fatigue

    Zhitong·
    SZ
    002317
    -2.30%
    Zhitong·
    SZ
    002317
    -2.30%

    ZHONGSHENGYAOYE's subsidiary has obtained ethical approval for the Phase III clinical trial of the innovative drug Anglatide granules

    ZHONGSHENGYAOYE's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has obtained ethical approval to conduct Phase III clinical trials of the innovative drug Anladiwei granules in children aged 2 to 11 years. This drug is the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, and it is expected to be approved for market launch in May 2025

    Zhitong·
    SZ
    002317
    -2.30%
    Zhitong·
    SZ
    002317
    -2.30%

    ZHONGSHENGYAOYE released its performance for the first half of the year, with a net profit attributable to the parent company of 188 million yuan, a year-on-year increase of 114.96%

    According to the Zhitong Finance APP, ZHONGSHENGYAOYE released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. The net profit attributable to shareholders of the listed company was 188 million yuan, a year-on-year increase of 114.96%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 187 million yuan, a year-on-year increase of 7.42%. The basic earnings per share were 0.22 yuan

    Zhitong·
    SZ
    002317
    -2.30%
    Zhitong·
    SZ
    002317
    -2.30%
    © 2025 Longbridge｜Disclaimer